...
首页> 外文期刊>Clinical Endocrinology >Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.
【24h】

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.

机译:密码子790和791的RET突变携带者之间的甲状腺髓样癌的发展差异。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVES: Hereditary medullary thyroid carcinoma (MTC) is caused by germ-line mutations in the RET proto-oncogene. Our study addresses the difference in development of MTC between rare mutations in RET codons 790, 791 and 804. DESIGN: We evaluated tumour stage, calcitonin levels, biochemical cure rates and associated endocrinopathies in 153 German/Austrian patients with RET 790 (n = 47), 791 (n = 56) and 804 mutations (n = 50), divided into index- and screening groups. RESULTS: Age at diagnosis in index-patients did not differ significantly among the three codon groups (medians of 57, 61 and 53 years). Tumour stage at diagnosis was significantly less advanced with codon 791 (n = 22) than 790 (n = 16) and 804 (n = 16) mutations (P = 0.001). In screening patients, age at diagnosis did not differ significantly among the three groups (medians 19, 24 and 32 years). Tumour stage at diagnosis was also significantly less advanced with codon 791 (n = 34) than 790 (n = 31) and 804 (n = 34) (P = 0.032). Preoperative basal calcitonin levels were significantly lower in codon 791 carriers compared to codon 790 carriers, and cure rates were significantly higher in both index (75%vs. 31%; P = 0.03) and screening patients (100%vs. 75%; P = 0.015). Additional endocrinopathies were observed only with codon 791 carriers (four pheochromocytomas and two hyperparathyroidism). CONCLUSION: There is a significant difference in MTC development with less extensive C-cell disease, higher cure rate and more frequent additional endocrinopathies in carriers of RET codon 791 mutations compared with carriers of codons 790 and 804 mutations. This information should be considered when age of prophylactic thyroidectomy is discussed.
机译:目的:遗传性甲状腺髓样癌(MTC)是由RET原癌基因的种系突变引起的。我们的研究解决了RET密码子790、791和804中罕见突变之间MTC的发展差异。设计:我们评估了153名德国/奥地利RET 790患者的肿瘤分期,降钙素水平,生化治愈率和相关的内分泌病(n = 47) ),791(n = 56)和804突变(n = 50),分为索引和筛选组。结果:三个密码子组(中位年龄分别为57、61和53岁)之间,索引患者的诊断年龄没有显着差异。密码子791(n = 22)在诊断时的肿瘤分期比790(n = 16)和804(n = 16)突变的晚期明显降低(P = 0.001)。在筛查患者时,三组之间的诊断年龄没有显着差异(中位数为19、24和32岁)。使用791号密码子(n = 34)时,诊断时的肿瘤分期也明显低于790号密码子(n = 31)和804号密码子(n = 34)(P = 0.032)。密码子791携带者的术前基础降钙素水平明显低于密码子790携带者,治愈率在两个指标(75%vs。31%; P = 0.03)和筛查患者(100%vs。75%; P)中均显着较高。 = 0.015)。仅在791个密码子携带者(4个嗜铬细胞瘤和2个甲状旁腺功能亢进)中观察到了其他内分泌病变。结论:与密码子790和804突变携带者相比,RET密码子791携带者的C细胞疾病少,治愈率高和附加内分泌病多,MTC的发展存在显着差异。当讨论预防性甲状腺切除术的年龄时,应考虑该信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号